Back to PFEView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in Growth Hormone Deficiency
View Full LandscapeDrug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA2/14/2022
Ngenla
Indicated for the long-term treatment of paediatric patients with growth disturbance due to insufficient secretion of growth hormone
Orphan
View on EMADrug Science
Mechanism of action & safety profile
Related Pipeline
13 valent pneumococcal conjugate vaccine with Polysorbate 80Phase 3
Vaccines, Pneumococcal
Insulin LisproPhase 3
Diabetes Mellitus
Cyclosporine APhase 3
Renal Transplantation
DVS-233 SR (desvenlafaxine sustained release )Phase 3
Major Depressive Disorder
MeropenemPhase 3
Complicated Intra-abdominal Infections
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts